ESR2 and neoplasm: To identify alternative therapeutic compounds capable of eliciting similar transcriptomic responses, and thus perhaps capable of recapitulating ERβ’s tumor suppressive activity even in the absence of ERβ expression, we used the publicly available PharmOmics pipeline (Mergeomics) [23,26] to independently analyze the E2-regulated gene sets from each of our cell line models (parental, D-R, and P-R).